Literature DB >> 10456219

Metabolism of apolipoproteins AI and AII in a patient with paradoxical reduction in high-density lipoprotein due to ciprofibrate.

L Beghin1, N Capps, N Duhal, J Davies, B Staels, G Luc.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10456219     DOI： 10.1177/000456329903600420

Source DB:  PubMed          Journal:  Ann Clin Biochem        ISSN： 0004-5632            Impact factor:   2.057


× No keyword cloud information.
  4 in total

Review 1.  Approach to the patient with extremely low HDL-cholesterol.

Authors:  Daniel J Rader; Emil M deGoma
Journal:  J Clin Endocrinol Metab       Date:  2012-10       Impact factor: 5.958

2.  Targeted Proteomics Identifies Paraoxonase/Arylesterase 1 (PON1) and Apolipoprotein Cs as Potential Risk Factors for Hypoalphalipoproteinemia in Diabetic Subjects Treated with Fenofibrate and Rosiglitazone.

Authors:  Graziella E Ronsein; Gissette Reyes-Soffer; Yi He; Michael Oda; Henry Ginsberg; Jay W Heinecke
Journal:  Mol Cell Proteomics       Date:  2015-12-14       Impact factor: 5.911

3.  Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin.

Authors:  Michel Farnier; Qian Dong; Arvind Shah; Amy O Johnson-Levonas; Philippe Brudi
Journal:  Lipids Health Dis       Date:  2011-11-16       Impact factor: 3.876

4.  Paradoxical reduction in HDL-C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: the ACCORD Lipid Trial.

Authors:  Peter E Linz; Laura C Lovato; Robert P Byington; Patrick J O'Connor; Lawrence A Leiter; Daniel Weiss; Rex W Force; John R Crouse; Faramarz Ismail-Beigi; Debra L Simmons; Vasilios Papademetriou; Henry N Ginsberg; Marshall B Elam
Journal:  Diabetes Care       Date:  2013-12-02       Impact factor: 19.112
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.